Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 20/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.38 |
| ▸ | DPP7 | Q9UHL4 | 5/20 | 0.37 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.35 |
| ▸ | FAP | Q12884 | 1/20 | 0.35 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12476418 | 0.84 | DPP4 (0.41) | DPP4CYP2D6DPP7DPP9DPP8 | |
| SCHEMBL15740038 | 0.84 | DPP4 (0.41) | DPP4CYP2D6DPP7DPP9DPP8 | |
| SCHEMBL15740022 | 0.84 | DPP4 (0.42) | DPP4CYP2D6DPP7DPP9DPP8 | |
| SCHEMBL12477297 | 0.84 | DPP4 (0.46) | DPP4DPP7DPP9DPP8KCNH2 | |
| SCHEMBL15739881 | 0.84 | DPP4 (0.46) | DPP4DPP7DPP9DPP8KCNH2 | |
| Hydrochloric Acid SCHEMBL12476875 | 0.83 | DPP4 (0.46) | DPP4DPP7DPP9DPP8KCNH2 | |
| SCHEMBL3535589 | 0.82 | DPP4 (0.47) | DPP4CYP2D6DPP7DPP9DPP8 | |
| SCHEMBL12476768 | 0.81 | DPP4 (0.45) | DPP4CYP2D6DPP7DPP9FAP | |
| SCHEMBL3532203 | 0.81 | DPP4 (0.35) | DPP4CYP2D6DPP7DPP9DPP8 | |
| SCHEMBL2471779 | 0.81 | DPP4 (0.33) | DPP4CYP2D6DPP7DPP9DPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1819674-B1 | FUSED AMINOPIPERIDINES AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK SHARP & DOHME (US) | 2011-10-05 | — | — | EP | disclosed |
| US-7718667-B2 | Fused aminopiperidines as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes | MERCK SHARP & DOHME CORP. (US) | 2010-05-18 | — | — | US | disclosed |
| US-20080009510-A1 | Fused Aminopiperidine as Dipeptidyl Peptidase-IV Inhibitors for the Treatment or Prevention of Diabetes | MERCK SHARP & DOHME LLC | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009510-A1 | Fused Aminopiperidine as Dipeptidyl Peptidase-IV Inhibitors for the Treatment or Prevention of Diabetes | DPP4, DPP3, DPP7 | DPP4 1/4885CYP2D6 558/4885DPP7 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.